SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (350)3/26/2003 1:48:27 PM
From: keokalani'nui  Read Replies (1) of 625
 
Whether abt's other licensor was "needed" will provide for a nice dispute as it sounds like an objective standard.

It does seem to point to DYAX, since the H royalty in the x-license with dyax recently was announced in vaguely qualified terms, as 'potential' or 'under certain conditions' or something to that effect. How is dyax stock doing anyway, since the question will be--if it is them--whether they will get a double dip of H; though it's hard to see how a double dip, without any other consideration, would be allowed by any judge.

With luck this is only a matter of ABT starting a process to figure out how to pay only once. Plus there is the royalty buy-out option.

Take it easy on yourself, I don't see how this will teach anyone to dig deeper for there is no way to know what is going on still. It all depends on what management tells us peons anyway.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News